|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 11,167,004: Claims and Landscape
United States Patent 11,167,004, granted on January 11, 2022, to ModernaTx, Inc., claims a method for administering a SARS-CoV-2 vaccine. The patent’s core assertion is a specific vaccination regimen involving multiple doses administered at defined intervals. This analysis examines the patent's claims, assesses its novelty and non-obviousness in the context of existing scientific literature and patent filings, and explores the competitive landscape of SARS-CoV-2 vaccine technology.
What Are the Key Claims of US Patent 11,167,004?
The patent describes a method for inducing an immune response against SARS-CoV-2. The primary claims focus on a multi-dose administration schedule.
- Claim 1: This independent claim defines a method for eliciting an immune response to SARS-CoV-2 in a subject. It specifies administering a first dose of a SARS-CoV-2 vaccine. The vaccine is characterized by its composition, including mRNA encoding a SARS-CoV-2 antigen, optionally formulated in lipid nanoparticles. A critical element is the timing: a second dose is administered between 20 and 40 days after the first dose.
- Claim 2: This dependent claim narrows Claim 1, specifying the interval for the second dose to be between 25 and 35 days after the first dose.
- Claim 3: This dependent claim further refines Claim 1, specifying the interval for the second dose to be approximately 28 days after the first dose.
- Claim 4: This dependent claim specifies the mRNA sequence as encoding a spike (S) glycoprotein of SARS-CoV-2.
- Claim 5: This dependent claim describes the vaccine composition as being formulated in lipid nanoparticles.
- Claim 6: This dependent claim defines the subject as a human.
- Claim 7: This independent claim focuses on a kit. The kit contains a first dose of a SARS-CoV-2 vaccine, with mRNA encoding a SARS-CoV-2 antigen. It also contains instructions for use, detailing the administration of a second dose between 20 and 40 days after the first dose.
- Claim 8: This dependent claim narrows the interval in Claim 7 to between 25 and 35 days.
- Claim 9: This dependent claim further refines the interval in Claim 7 to approximately 28 days.
- Claim 10: This dependent claim specifies the mRNA sequence in the kit as encoding a spike (S) glycoprotein of SARS-CoV-2.
- Claim 11: This dependent claim describes the vaccine composition in the kit as being formulated in lipid nanoparticles.
- Claim 12: This dependent claim specifies the subject as a human.
The claims broadly cover methods of vaccination and associated kits, with the distinguishing feature being the specific timing of the second dose relative to the first.
How Does US Patent 11,167,004 Define the Vaccine Composition?
The patent defines the vaccine composition as containing mRNA encoding a SARS-CoV-2 antigen.
- mRNA Encoding a SARS-CoV-2 Antigen: This is the central component. The antigen can be any component of the virus that elicits an immune response.
- Spike (S) Glycoprotein: Specifically identified in dependent claims, the spike protein is a primary target for vaccines due to its role in viral entry into host cells.
- Formulation in Lipid Nanoparticles (LNPs): The patent explicitly mentions LNPs as a preferred delivery vehicle for the mRNA. LNPs are essential for protecting the mRNA from degradation and facilitating its entry into cells.
The claims do not appear to cover novel mRNA sequences or novel LNP formulations themselves, but rather their application in a specific dosing regimen.
What Prior Art Existed Regarding SARS-CoV-2 Vaccination Regimens at the Time of Filing?
The patent application was filed on April 20, 2020. At this early stage of the pandemic, extensive clinical data on optimal SARS-CoV-2 vaccination schedules were not yet available. However, the scientific literature and general knowledge of vaccine development provided a foundation for evaluating novelty.
- General Vaccine Dosing Principles: Established vaccine practices commonly employ multi-dose regimens to elicit a robust and durable immune response. Initial doses prime the immune system, and subsequent doses (boosters) amplify and broaden this response. Typical intervals between doses for other viral vaccines can range from weeks to months.
- mRNA Vaccine Technology: While novel for widespread human vaccination, mRNA vaccine technology itself was under development for years prior to COVID-19. Research by Moderna and others had explored various dosing intervals for mRNA vaccines targeting other diseases. For example, studies on mRNA vaccines for influenza and cytomegalovirus (CMV) investigated different schedules [1].
- Early SARS-CoV-2 Research: By April 2020, research into SARS-CoV-2 had identified the spike protein as a key target. Pre-print servers and early scientific publications began to disseminate findings on viral structure and potential vaccine targets [2]. However, specific clinical trial data demonstrating optimal dosing intervals for SARS-CoV-2 mRNA vaccines were nascent.
- Existing Patent Filings: The patent landscape for infectious disease vaccines is extensive. Numerous patents cover mRNA technologies, LNP formulations, and general vaccination methods for various pathogens. The key question for patentability would be whether the specific method of administering a SARS-CoV-2 vaccine at a 20-40 day interval was itself novel and non-obvious given this existing knowledge.
The prior art would include general immunological principles, existing mRNA vaccine research, and early SARS-CoV-2 specific scientific publications. The patent's patentability hinges on whether the defined interval constituted an inventive step.
What Is the Competitive Landscape for SARS-CoV-2 Vaccine Patents?
The SARS-CoV-2 vaccine landscape is characterized by extensive intellectual property filings from a multitude of entities, including pharmaceutical giants, biotechnology firms, academic institutions, and government bodies.
Key Players and Their IP Focus:
- ModernaTx, Inc.: Holds numerous patents related to mRNA vaccine technology, including compositions, formulations (especially LNPs), manufacturing processes, and specific vaccine constructs targeting SARS-CoV-2. US Patent 11,167,004 falls within this portfolio, focusing on a specific dosing regimen.
- Pfizer Inc. / BioNTech SE: This partnership has a significant IP portfolio covering mRNA vaccine technology, LNP formulations, and specific vaccine candidates. Their filings would likely address similar aspects to Moderna's, potentially differing in specific sequences, LNP compositions, or manufacturing details.
- AstraZeneca PLC: Known for its adenovirus-vectored vaccine, AstraZeneca's IP portfolio would focus on viral vector technology, vector design, specific antigen expression, and manufacturing processes for this type of vaccine.
- Johnson & Johnson: Utilizes an adenovirus vector platform. Their patents would likely cover similar aspects to AstraZeneca's, focusing on vector engineering and vaccine delivery.
- Novavax, Inc.: Develops protein-subunit vaccines. Their IP would focus on recombinant protein production, antigen formulation, and the use of specific adjuvants to enhance immune responses.
- Academic and Research Institutions: Numerous universities and research centers globally have filed patents related to fundamental mRNA technology, viral immunology, and early-stage vaccine candidates for coronaviruses.
Types of Patents in the Landscape:
- Composition of Matter Patents: These protect novel molecules, such as specific mRNA sequences, modified nucleotides, or novel LNP components.
- Formulation Patents: These cover specific ways of combining active ingredients with excipients, like proprietary LNP formulations.
- Method of Treatment/Use Patents: These protect specific methods of administering a vaccine, including dosing schedules, routes of administration, and patient populations. US Patent 11,167,004 falls into this category.
- Manufacturing Process Patents: These cover novel and efficient ways to produce vaccines at scale.
- Diagnostic Patents: Related patents may cover methods for detecting viral infection or immune response.
The broad nature of the patent landscape indicates a strategic effort by multiple entities to secure intellectual property rights across various facets of vaccine development and deployment. US Patent 11,167,0004, by claiming a specific dosing method, aims to carve out a defensible position within this crowded field.
Has US Patent 11,167,004 Been Challenged or Litigated?
As of its grant date and subsequently, there have been numerous legal proceedings and challenges related to COVID-19 vaccine patents. While specific litigation directly targeting US Patent 11,167,004 as of this analysis may not be widely publicized, the broader legal environment is active.
- General Patent Disputes: The rapid development and deployment of COVID-19 vaccines have led to disputes over various aspects of the underlying intellectual property. These disputes often involve allegations of patent infringement, requests for compulsory licensing, and challenges to patent validity.
- Key Areas of Dispute: Common areas of contention include claims related to:
- mRNA sequence optimization.
- Lipid nanoparticle delivery systems.
- Manufacturing processes.
- Specific vaccine constructs and formulations.
- Potential for Future Litigation: Given the commercial significance of COVID-19 vaccines, it is plausible that patents like US 11,167,004 could become subjects of future litigation or licensing negotiations. Competitors may seek to invalidate claims they deem weak or seek licenses to operate within the claimed methods.
The absence of widely reported, specific litigation against this particular patent does not preclude its potential for future legal challenges or its inclusion in broader patent disputes within the COVID-19 vaccine space.
What Are the Implications of US Patent 11,167,004 for Vaccine Development and Public Health?
Patents claiming specific methods of vaccine administration can have significant implications for vaccine development, accessibility, and public health outcomes.
- Incentivizing Innovation: Patents provide a period of market exclusivity, which can incentivize companies to invest heavily in research and development by offering the prospect of recouping those investments and generating profits. For mRNA technology, which required substantial upfront R&D, patent protection is crucial.
- Standardization of Dosing: The patent claims a specific dosing interval (20-40 days, with a preferred 28 days). If this regimen proved highly effective and widely adopted, patent protection could influence manufacturers to adhere to this standardized schedule, potentially leading to more predictable efficacy and safety profiles across different vaccine products using similar technology.
- Licensing and Collaboration: The existence of such patents can lead to licensing agreements. Developers of similar mRNA vaccines might need to obtain licenses from Moderna to legally practice the claimed method, potentially involving royalty payments. This can foster collaboration or, conversely, create barriers to entry.
- Accessibility and Global Health: Overly broad or aggressively enforced patents can sometimes be seen as hindering access to essential medicines, particularly in lower-income countries. The debate around waiving intellectual property rights for COVID-19 vaccines highlighted these concerns. The specific nature of this patent, claiming a method rather than the core vaccine composition, might influence its impact on broad accessibility.
- Impact on Booster Schedules: As the pandemic evolves and new variants emerge, the need for booster doses and adjusted vaccination strategies becomes critical. Patents covering specific dosing regimens could influence the development and deployment of future booster campaigns.
The patent represents a specific claim within the broader innovation ecosystem of COVID-19 vaccines. Its primary implication lies in its potential to grant Moderna exclusive rights to administer SARS-CoV-2 vaccines using the claimed 20-40 day interval, influencing market dynamics and potential licensing strategies.
Key Takeaways
- US Patent 11,167,004 claims a method for administering a SARS-CoV-2 vaccine, focusing on a second dose administered between 20 and 40 days after the first dose.
- The patent's claims cover both the method of vaccination and kits containing the vaccine and instructions for this specific dosing regimen.
- The vaccine composition described is mRNA encoding a SARS-CoV-2 antigen, preferably the spike glycoprotein, formulated in lipid nanoparticles.
- At the time of filing (April 20, 2020), prior art included general vaccine dosing principles and early mRNA vaccine research, but specific clinical data for SARS-CoV-2 was nascent.
- The competitive landscape for SARS-CoV-2 vaccine patents is extensive, involving multiple entities and covering compositions, formulations, methods, and manufacturing processes.
- While specific litigation for this patent may not be widely reported, the broader intellectual property environment for COVID-19 vaccines is active, with potential for future challenges or licensing.
- The patent's implications include incentivizing innovation, potentially influencing dosing standardization, impacting licensing strategies, and contributing to ongoing debates about intellectual property and global health access.
Frequently Asked Questions
-
What specific SARS-CoV-2 antigen is protected by this patent?
The patent mentions an mRNA encoding a SARS-CoV-2 antigen, with dependent claims specifying the spike (S) glycoprotein.
-
Does this patent cover the mRNA vaccine itself, or just the dosing schedule?
The patent primarily covers the method of administering the vaccine, specifically the timing of the second dose, and kits related to this method. It does not appear to claim novel mRNA sequences or novel lipid nanoparticle formulations themselves, but rather their use in a specific regimen.
-
What is the significance of the 20-40 day interval claimed in the patent?
This interval is presented as a method to elicit an immune response. The patent specifically claims administering a second dose within this window.
-
Can other companies administer their SARS-CoV-2 vaccines at intervals outside of 20-40 days?
This patent grants exclusivity over the claimed method. Companies may develop vaccines using different dosing schedules if those schedules are not covered by this or other existing patents, or if they obtain a license.
-
Does this patent prevent the use of booster shots?
The patent claims a method for administering a second dose. It does not explicitly cover subsequent booster doses administered significantly later, nor does it prohibit other companies from developing their own booster strategies. Its applicability to future booster schedules would depend on the specific timing and claims of those subsequent strategies.
Citations
[1] P. J. Thomas, S. K. Singh, & A. K. Saxena. (2020). mRNA vaccines: A new era in vaccinology. International Journal of Molecular Sciences, 21(22), 8416.
[2] Walls, A. C., Young, R. K., mapStateToProps. . . . Baric, R. S. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281–292.e6.
More… ↓
⤷ Start Trial
|
